FIELD: medicine.
SUBSTANCE: invention relates to medicine and concerns a method for the treatment of human platinum-resistant metastatic ovarian cancer. The method includes administration to a patient of a therapeutically effective dose of a soluble variant of AXL polypeptide, where the soluble variant of AXL polypeptide does not have a transmembrane AXL domain; does not have a fibronectin (FN) domain; has one Ig1 domain and one Ig2 domain; and has a number of amino acid modifications of AXL sequence of a wild type (SEQ ID NO: 1), consisting of: Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg; where the specified number of amino acid modifications increases affinity of binding of AXL polypeptide with growth arrest specific protein 6 (GAS6), and where the soluble variant of AXL polypeptide is fused with Fc region with a peptide linker. At the same time, the administration scheme includes 15 mg/kg of the soluble variant of polypeptide AXL, administered every two weeks, and 80 mg/m2 of paclitaxel administered once a week.
EFFECT: method provides for effective and safe treatment of platinum-resistant ovarian cancer.
4 cl, 9 dwg, 3 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
COMBINATION | 2015 |
|
RU2744841C2 |
INHIBITORY PATHWAY NEUTRALIZATION IN LYMPHOCYTES | 2017 |
|
RU2769569C2 |
METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
RECEPTOR FOR VISTA | 2019 |
|
RU2812846C2 |
A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
Authors
Dates
2022-12-14—Published
2018-11-05—Filed